Roth Capital Starts Fate Therapeutics (FATE) at Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Roth Capital initiated coverage on Fate Therapeutics (NASDAQ: FATE) with a Buy rating and a price target of $8.00.
Shares of Fate Therapeutics closed at $3.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Cuts Price Target on Entergy (ETR) to $74 Following new Guidance
- Longbow Research Starts Five Below (FIVE) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!